NCT03066206 2026-02-20
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
7 trialsNCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT05045404 2023-09-13
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04044170 2020-11-17
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Hanmi Pharmaceutical Company Limited
Phase 2 Terminated
NCT02979821 2018-05-24
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Korean Association for the Study of Targeted Therapy
Phase 2 Completed
NCT01819428 2016-03-01
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
National OncoVenture
Phase 2 Terminated